REGENERON PHARMACEUTICALS, INC. (REGN) Dividend Safety
- Dividend payout ratio · 12 months: Value 8.74%; Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | 8.74% | Cash dividends paid / net income. Period ending 2026-06-30. $378.50M ÷ $4.33B × 100 ≈ 8.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | 378.50M USD | Payments of Dividends |
| Net income · 12 months | 4.33B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | $378.50M | $4.33B | 8.74% |
| 2026-03-31 | $374.30M | $4.42B | 8.46% |
| 2025-12-31 | $370.30M | $4.50B | 8.22% |
| 2025-09-30 | (m) | $4.58B | (m) |
| 2025-06-30 | (m) | $4.46B | (m) |
| 2025-03-31 | (m) | $4.50B | (m) |
| 2024-12-31 | (m) | $4.41B | (m) |
| 2024-09-30 | (m) | $4.65B | (m) |
| 2024-06-30 | (m) | $4.32B | (m) |
| 2024-03-31 | (m) | $3.86B | (m) |
| 2023-12-31 | (m) | $3.95B | (m) |
| 2023-09-30 | (m) | $3.99B | (m) |
| 2023-06-30 | (m) | $4.30B | (m) |
| 2023-03-31 | (m) | $4.18B | (m) |
| 2022-12-31 | (m) | $4.34B | (m) |
| 2022-09-30 | (m) | $5.37B | (m) |
| 2022-06-30 | (m) | $5.69B | (m) |
| 2022-03-31 | (m) | $7.93B | (m) |
| 2021-12-31 | (m) | $8.08B | (m) |
| 2021-09-30 | (m) | $7.00B | (m) |
| 2021-06-30 | (m) | $6.21B | (m) |
| 2021-03-31 | (m) | $4.00B | (m) |
| 2020-12-31 | (m) | $3.51B | (m) |
| 2020-09-30 | (m) | $3.16B | (m) |
| 2020-06-30 | (m) | $2.98B | (m) |
| 2020-03-31 | (m) | $2.28B | (m) |
| 2019-12-31 | (m) | $2.12B | (m) |
| 2019-09-30 | (m) | $2.14B | (m) |
| 2019-06-30 | (m) | $2.07B | (m) |
| 2019-03-31 | (m) | $2.43B | (m) |
| 2018-12-31 | (m) | $2.44B | (m) |
| 2018-09-30 | (m) | $1.80B | (m) |
| 2018-06-30 | (m) | $1.59B | (m) |
| 2018-03-31 | (m) | $1.43B | (m) |
| 2017-12-31 | (m) | $1.20B | (m) |
| 2017-09-30 | (m) | $1.28B | (m) |
| 2017-06-30 | (m) | $1.15B | (m) |
| 2017-03-31 | (m) | $963.07M | (m) |
| 2016-12-31 | (m) | $895.52M | (m) |
| 2016-09-30 | (m) | $797.40M | (m) |
| 2016-06-30 | (m) | $743.00M | (m) |
| 2016-03-31 | (m) | $725.77M | (m) |
| 2015-12-31 | (m) | $636.06M | (m) |
| 2015-09-30 | (m) | $571.16M | (m) |
| 2015-06-30 | (m) | $444.13M | (m) |
| 2015-03-31 | (m) | $345.84M | (m) |
| 2014-12-31 | (m) | $348.07M | (m) |
| 2014-09-30 | (m) | $334.70M | (m) |
| 2014-06-30 | (m) | $396.29M | (m) |
| 2014-03-31 | (m) | $390.93M | (m) |
| 2013-12-31 | (m) | $424.36M | (m) |
| 2013-09-30 | (m) | $797.96M | (m) |
| 2013-06-30 | (m) | $848.13M | (m) |
| 2013-03-31 | (m) | $837.49M | (m) |
| 2012-12-31 | (m) | $750.27M | (m) |
| 2012-09-30 | (m) | $226.42M | (m) |
| 2012-06-30 | (m) | $-27.41M | (m) |
| 2012-03-31 | (m) | $-166.66M | (m) |
| 2011-12-31 | (m) | $-221.76M | (m) |
| 2011-09-30 | (m) | $-182.91M | (m) |
| 2011-06-30 | (m) | $-154.42M | (m) |
| 2011-03-31 | (m) | $-117.39M | (m) |
| 2010-12-31 | (m) | $-104.47M | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) |
| 2009-12-31 | (m) | $-67.83M | (m) |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2008-12-31 | (m) | $-79.13M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |